In Vitro Inhibition of Histamine Release Behavior of Cetirizine Intercalated into Zn/Al- and Mg/Al-Layered Double Hydroxides

Hussein‐Al‐Ali, Samer Hasan; Al‐Qubaisi, Mothanna Sadiq; Hussein, Mohd Zobir; Ismail, Maznah; Zainal, Zulkarnain; Hakim, Muhammad Nazrul

doi:10.3390/ijms13055899

Cited by 29 publications

(27 citation statements)

References 30 publications

(30 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…22 Meanwhile, in another report, Chang liver cells exposed to an LDH nanolayer also exhibited a slight decrease in viability compared with those exposed to its nanocomposite containing cetirizine. 23 Our findings are supported by the above-mentioned studies using nanolayers and their corresponding nanocomposites. The results also indicate that our nanocomposite is likely to be a biocompatible product because it shows less cytotoxicity than pristine The fitting results of the drug release profiles at pH 7.4 and 4.8 based on the three different kinetic models are shown in Figure 7.…”

Section: Surface Propertiessupporting

confidence: 80%

Development of a controlled-release anti-parkinsonian nanodelivery system using levodopa as the active agent

Kura¹,

Ali²,

Hussein³

et al. 2013

IJN

Self Cite

View full text Add to dashboard Cite

Abstract:A new layered organic-inorganic nanocomposite material with an anti-parkinsonian active compound, L-3-(3,4-dihydroxyphenyl) alanine (levodopa), intercalated into the inorganic interlayers of a Zn/Al-layered double hydroxide (LDH) was synthesized using a direct coprecipitation method. The resulting nanocomposite was composed of the organic moiety, levodopa, sandwiched between Zn/Al-LDH inorganic interlayers. The basal spacing of the resulting nanocomposite was 10.9 Å. The estimated loading of levodopa in the nanocomposite was approximately 16% (w/w). A Fourier transform infrared study showed that the absorption bands of the nanocomposite were characteristic of both levodopa and Zn/Al-LDH, which further confirmed intercalation, and that the intercalated organic moiety in the nanocomposite was more thermally stable than free levodopa. The resulting nanocomposite showed sustained-release properties, so can be used in a controlled-release formulation. Cytotoxicity analysis using an MTT assay also showed increased cell viability of 3T3 cells exposed to the newly synthesized nanocomposite compared with those exposed to pure levodopa after 72 hours of exposure.

show abstract

Section: Surface Propertiessupporting

confidence: 80%

Development of a controlled-release anti-parkinsonian nanodelivery system using levodopa as the active agent

Kura¹,

Ali²,

Hussein³

et al. 2013

IJN

Self Cite

View full text Add to dashboard Cite

show abstract

“…Further evaluation via the formalin test suggested that liposome-encapsulated diclofenac is more effective in suppressing inflammatory pain and that stronger peripheralmediated antinociceptive activity could be attained using the present liposomal formulations. Indeed, encapsulation with liposomes 29 or other materials [30][31][32] will significantly improve a drug's efficacy, and thus reduce its side effects by using lower doses. 33 Similarly to other NSAIDs, the usage of diclofenac is often associated with gastric mucosal erosion, ulceration, hemorrhage, epigastric pain, and platelet dysfunction owing to the inhibition of prostaglandin synthesis by cyclooxygenase enzyme (COX).…”

Section: Discussionmentioning

confidence: 99%

Evaluation of antinociceptive activity of nanoliposome-encapsulated and free-form diclofenac in rats and mice

Goh

Tang

Chiong

et al. 2014

IJN

View full text Add to dashboard Cite

Diclofenac is a nonsteroidal anti-inflammatory drug (NSAID) that exhibits anti-inflammatory, antinociceptive, and antipyretic activities. Liposomes have been shown to improve the therapeutic efficacy of encapsulated drugs. The present study was conducted to compare the antinociceptive properties between liposome-encapsulated and free-form diclofenac in vivo via different nociceptive assay models. Liposome-encapsulated diclofenac was prepared using the commercialized proliposome method. Antinociceptive effects of liposome-encapsulated and free-form diclofenac were evaluated using formalin test, acetic acid-induced abdominal writhing test, Randall–Selitto paw pressure test, and plantar test. The results of the writhing test showed a significant reduction of abdominal constriction in all treatment groups in a dose-dependent manner. The 20 mg/kg liposome-encapsulated diclofenac demonstrated the highest antinociceptive effect at 78.97% compared with 55.89% in the free-form group at equivalent dosage. Both liposome-encapsulated and free-form diclofenac produced significant results in the late phase of formalin assay at a dose of 20 mg/kg, with antinociception percentages of 78.84% and 60.71%, respectively. Significant results of antinociception were also observed in both hyperalgesia assays. For Randall–Sellito assay, the highest antinociception effect of 71.38% was achieved with 20 mg/kg liposome-encapsulated diclofenac, while the lowest antinociceptive effect of 17.32% was recorded with 0 mg/kg liposome formulation, whereas in the plantar test, the highest antinociceptive effect was achieved at 56.7% with 20 mg/kg liposome-encapsulated diclofenac, and the lowest effect was shown with 0 mg/kg liposome formulation of 8.89%. The present study suggests that liposome-encapsulated diclofenac exhibits higher antinociceptive efficacy in a dose-dependent manner in comparison with free-form diclofenac.

show abstract

“…14 Owing to the efficient drug-delivery feature of LDH nanocarriers, many pharmaceutically active compounds have been successfully intercalated into the interlayer gallery of LDH. Among them are the cardiovascular drugs fluvastatin and pravastatin; 15 anti-inflammatory drugs such as diclofenac 16 and fenbufen; 17 antihypertensive drugs like perindopril erbumine; 18,19 the antihistamine drug cetirizine hydrochloric acid; 20 and anticancer drugs such as cordycepin, which was intercalated into the gallery of magnesium/ aluminum (Mg/Al)-LDH. It was observed that the resulting nanohybrid had greater stability and a greater suppression effect on U937 cancer cell growth than free cordecypin 3 and methotrexate (MTX).…”

Section: Introductionmentioning

confidence: 99%

Preparation and controlled-release studies of a protocatechuic acid-magnesium/aluminum-layered double hydroxide nanocomposite

Barahuie¹,

Hussein²,

Hussein‐Al‐Ali³

et al. 2013

IJN

Self Cite

View full text Add to dashboard Cite

Abstract:In the study reported here, magnesium/aluminum (Mg/Al)-layered double hydroxide (LDH) was intercalated with an anticancer drug, protocatechuic acid, using ionexchange and direct coprecipitation methods, with the resultant products labeled according to the method used to produce them: "PANE" (ie, protocatechuic acid-Mg/Al nanocomposite synthesized using the ion-exchange method) and "PAND" (ie, protocatechuic acid-Mg/Al nanocomposite synthesized using the direct method), respectively. Powder X-ray diffraction and Fourier transform infrared spectroscopy confirmed the intercalation of protocatechuic acid into the inter-galleries of Mg/Al-LDH. The protocatechuic acid between the interlayers of PANE and PAND was found to be a monolayer, with an angle from the z-axis of 8° for PANE and 15° for PAND. Thermogravimetric and differential thermogravimetric analysis results revealed that the thermal stability of protocatechuic acid was markedly enhanced upon intercalation. The loading of protocatechuic acid in PANE and PAND was estimated to be about 24.5% and 27.5% (w/w), respectively. The in vitro release study of protocatechuic acid from PANE and PAND in phosphate-buffered saline at pH 7.4, 5.3, and 4.8 revealed that the nanocomposites had a sustained release property. After 72 hours incubation of PANE and PAND with MCF-7 human breast cancer and HeLa human cervical cancer cell lines, it was found that the nanocomposites had suppressed the growth of these cancer cells, with a half maximal inhibitory concentration of 35.6 μg/mL for PANE and 36.0 μg/mL for PAND for MCF-7 cells, and 19.8 μg/mL for PANE and 30.3 μg/mL for PAND for HeLa cells. No half maximal inhibitory concentration for either nanocomposite was found for 3T3 cells.

show abstract

In Vitro Inhibition of Histamine Release Behavior of Cetirizine Intercalated into Zn/Al- and Mg/Al-Layered Double Hydroxides

Cited by 29 publications

References 30 publications

Development of a controlled-release anti-parkinsonian nanodelivery system using levodopa as the active agent

Development of a controlled-release anti-parkinsonian nanodelivery system using levodopa as the active agent

Evaluation of antinociceptive activity of nanoliposome-encapsulated and free-form diclofenac in rats and mice

Preparation and controlled-release studies of a protocatechuic acid-magnesium/aluminum-layered double hydroxide nanocomposite

Contact Info

Product

Resources

About